Green Thumb: Stifel Cuts Price Target To $73

Green Thumb Industries (CSE: GTII) reported its fourth-quarter and full-year financial results earlier this month. The company saw its revenues grow 60.5% year over year to $893.6 million while full-year earnings per share almost 5x to $0.34 per share, or a net income of $75.4 million. This is after paying $124.6 million in taxes for the year.

For the quarter, the company saw its growth slow as revenue, gross profits, and income before taxes grew 4.2%, 1.8%, and -14.3% this quarter respectively, compared to the 5.2%, 14.2%, and 10.5% growth it saw in the prior quarter. The company reported revenues of $243.6 million and a gross profit of $128.64 million for the fourth quarter.

A number of analysts slashed their 12-month price target, bringing the average down from C$55.41 to C$49.42, which represents a 145% upside to the current stock price. Green Thumb currently has 17 analysts covering it, with 5 having strong buy ratings and the other 12 having buy ratings. The street high sits at C$73, which represents a 262% upside.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

In Stifel-GMP’s fourth-quarter review, they reiterate their buy rating but cut their 12-month price target from C$80 to C$73 saying that their view on the results are neutral and believes investors “may see a temporary period of muted growth as the company prepares for first harvests beginning in H2/22.” Combined with a number of states looking to be recreational in the near term, Stifel-GMP believes this will offer investors a “step-change” in the company’s growth profile.

For the quarterly results, Stifel expected revenues of $243 million, in line with the results. While gross profits of $129.5 million came in below their estimate of $133.4 million. Additionally, adjusted EBITDA of $81.2 million came in slightly lower than their $82.3 million estimates. Though, Green Thumb did beat on adjusted net income and earnings per share with the company almost doubling the estimate of $12.3 million and $0.05.

Stifel-GMP notes that management reported pricing pressures in both retail and wholesale across the board but mainly in Pennslyvania and Nevada. Stifel adds that basket sizes have also come down while the volume of purchases remains fairly stable. Stifel believes that the mid-to-low quality products have seen the most price compression as competitors continue to try and buy market share.

Lastly, you can see Stifel’s update estimates as they have lowered them off the back of “limited visibility to returning price competition and cost inflation, which flows through future quarters.” Though their estimates do not include any recreational sales from New Jersey, New York, or Connecticut.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Building a 500,000 Ounce a Year Gold Producer | Patrick Downey – Orezone Gold

Gold Giant Bets $57M on a 4 Million Ounce Target | Matt Manson – Radisson Mining

The Gold M&A Wave Will Create 10-Baggers | Tim Clark – Fury Gold Mines

Recommended

Homeland Nickel Signs Binding Offtake With Westwin for 20,000 Tonnes of Concentrate a Year

Golden Cariboo’s First Quesnelle Resource Estimate Tallies 1.19 Million Gold Equivalent Ounces

Related News

Microsoft: Analysts Anticipate Q4 Earnings Per Share Of $2.29

Microsoft (NASDAQ: MSFT) will be reporting its fiscal fourth quarter financials today after markets close....

Tuesday, July 26, 2022, 10:57:00 AM

Raymond James: Village Farms’ Revenue Miss Is An “Artifact of Consolidation”

Yesterday, Village Farms (TSX: VFF) (NASDAQ: VFF) reported fourth quarter and year-end earnings. The company...

Wednesday, March 17, 2021, 04:11:00 PM

Curaleaf Sees Numerous Analysts Raise Price Targets Following Third Quarter Results

On Tuesday, Curaleaf Holdings (CSE: CURA) reported their third quarter results. The company reported total...

Saturday, November 21, 2020, 01:27:00 PM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Well Health: Consensus Price Target Climbs To $11.83 Following MyHealth Acquisition

WELL Health Technologies Corp. (TSX: WELL) this week announced that they would be acquiring MyHealth...

Thursday, June 10, 2021, 11:46:00 AM